David Wraith

This inventor holds 14 USPTO granted patents and 12 published patent applications, plus 8 CIPO patents and 10 EPO patents. Top assignees: Apitope Technology (Bristol) Limited, Apitope International Nv, Worg Pharmaceuticals (Zhejiang) Co., Ltd.. Active years: 2006-2023.

USPTO Granted Patents = 14 (Patent Applications = 12)

% Patents Active = 71.4

CIPO Patents = 8 (Patent Applications = 6)

EPO Patents = 10 (Patent Applications = 17)

Average Co-Inventor Count = 1.7

ph-index = 2

Forward Citations = 104(Granted Patents)

Location History:

Bristol, GB (2006 - 2020)
Chepstow Gwent, GB (2020)
Chepstow, GB (2023)

Company Filing History:

8 out of 8

Apitope Technology (Bristol) Limited

patents

5 out of 5

Apitope International Nv

patents

1 out of 4

Worg Pharmaceuticals (Zhejiang) Co., Ltd.

patents

Years Active: 2006-2023

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11542316 - S-Arrestin peptides and therapeutic uses thereof (2023-01-03),

2. 10730919 - Peptides (2020-08-04),

3. 10646589 - Thyroid stimulating hormone receptor peptides and uses thereof (2020-05-12),

4. 10377800 - Myelin oligodendrocyte glycoprotein (MOG) peptide (2019-08-13),

5. 9938329 - Peptides (2018-04-10),

6. 9862751 - Myelin oligodendrocyte glycoprotein peptides (2018-01-09),

7. 9775880 - Methods of using myelin basis protein peptide compositions (2017-10-03),

8. 9381234 - Methods of using myelin basic protein peptide compositions (2016-07-05),

9. 8961986 - Peptide composition (2015-02-24),

10. 8703705 - Modified factor VIII peptides (2014-04-22),

11. 8623827 - Myelin basic protein peptide composition (2014-01-07),

12. 8445448 - FVIII peptides and their use in tolerising haemophiliacs (2013-05-21),

13. 8343500 - Peptide composition (2013-01-01),

14. 7071297 - Tolerogenic peptides from myelin basic protein (2006-07-04),

Title: The Innovative Contributions of David Wraith

Introduction

David Wraith is a distinguished inventor based in Bristol, GB, with a remarkable portfolio of 13 patents to his name. His work primarily focuses on advancements in immunology, particularly related to thyroid stimulating hormone receptor peptides and their applications in disease prevention and treatment.

Latest Patents

Among his latest innovations, Wraith has developed a peptide that is at least partially derivable from the human Thyroid Stimulating Hormone Receptor (TSHR). This peptide is notable for its ability to bind to an MHC molecule in vitro, presenting it to T cells without requiring further antigen processing. The invention serves a significant purpose, relating to the prevention or suppression of activating autoantibody formation in Graves' Disease. Another recent patent includes a composition comprising TSHR peptides, which can be utilized for the same therapeutic aims. The key amino acid sequences involved highlight the specificity and innovative nature of his work in addressing autoimmune conditions.

Career Highlights

Throughout his career, David Wraith has been affiliated with notable companies such as Apitope Technology Limited and Apitope International NV. His contributions at these organizations have helped advance research and therapeutic strategies in immunology.

Collaborations

Wraith has collaborated with talented individuals such as Heather Streeter and Mary Ponsford during his tenure in various research institutions. Their collective expertise has played a pivotal role in fostering innovative projects and developments in the field of immunotherapy.

Conclusion

David Wraith's contributions to the field of immunology through his numerous patents underscore his role as an influential inventor. His ongoing research and innovations continue to offer promising avenues for the prevention and treatment of autoimmune diseases, enhancing the potential for improved health outcomes.